Taken into consideration limitations of the in vitro systems in the assessment of agents affecting tumor microenvironment, we evaluated the utility of combined blockade of CXCL12/CXCR4 and TGF-β signaling pathways in the in vivo leukemia model. This evidence concerns the gene CXCL12 and leukemia.